Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment

Excerpt from the Press Release:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).

The Phase 3 real-world evidence study will evaluate the safety, efficacy, and cost-effectiveness of Cognito’s therapeutic platform in MCI patients treated within Providence Health Plan’s network of nationally renowned neurology specialists. This first of its kind registrational study is expected to begin in Q2 2022, running in parallel to Cognito’s pivotal Phase 3 study in patients with mild-to-moderate Alzheimer’s Disease (AD).

“Novel technologies, such as Cognito’s disease-modifying treatment are critical to improve patient outcomes in MCI,” said Dr. Nancy Isenberg, Medical Director, Center for Healthy Aging, Swedish Neuroscience Institute. “There are currently no drugs that have been approved for treating MCI, and patients need new safe, effective and affordable options.”

“We look forward to collaborating with Providence Health Plan on our Phase 3 programs evaluating our disease-modifying intervention across the full spectrum of patients from MCI to mild to moderate Alzheimer’s,” said Brent Vaughan, CEO, Cognito Therapeutics. “Our proprietary therapeutic platform holds the potential to create an entirely new approach to clinically meaningful improvements in patients across a broad range of conditions of neurodegeneration and neuropsychiatry.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release